Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2017 Summary Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Prostaglandin D2 (PGD2) receptors are G protein-coupled receptors that binds and is activated by prostaglandin D2. It mediates the pro-inflammatory chemotaxis of eosinophils, basophils, and Th2 lymphocytes generated during allergic inflammation. Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 3 respectively. Report covers products from therapy areas Respiratory, Dermatology, Immunology and Ophthalmology which include indications Asthma, Atopic Dermatitis, Allergic Asthma, Allergic Rhino-Conjunctivitis, Androgenic Alopecia, Allergic Rhinitis, Allergies, Chronic Obstructive Pulmonary Disease (COPD) and Inflammation. The latest report Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics and enlists all their major and minor projects - The report assesses Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Overview 7 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Assessment 14 Assessment by Mechanism of Action 14 Assessment by Route of Administration 15 Assessment by Molecule Type 16 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Companies Involved in Therapeutics Development 17 Allergan Plc 17 Boehringer Ingelheim GmbH 17 Brickell Biotech Inc 18 Idorsia Ltd 18 Merck & Co Inc 19 Novartis AG 19 Oxagen Ltd 20 Pulmagen Therapeutics LLP 20 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Drug Profiles 21 ACT-774312 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 ADC-3680 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 ADC-7405 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 ADC-9971 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 BBI-5000 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 BI-1060469 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 fevipiprant - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 MK-1029 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 OC-2417 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 setipiprant - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Timapiprant - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Dormant Products 38 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Discontinued Products 41 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Product Development Milestones 42 Featured News & Press Releases 42 Dec 14, 2016: Pulmagen Therapeutics announces positive data for ADC3680, a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II study conducted in Japan by partner Teijin Pharma 42 Sep 28, 2016: Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma 43 Aug 05, 2016: Asthma pill could reduce symptoms in severe sufferers 43 Feb 17, 2016: Update on Phase 2 clinical trial with OC459 in patients with moderate to severe atopic dermatitis 45 Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss 45 Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease 46 Oct 07, 2014: Atopix Therapeutics secures funding from SR One to advance development of CRTH2 antagonists in eosinophilic disease 47 Aug 01, 2014: Pulmagen's lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study 47 Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma 47 Nov 19, 2013: Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis 48 May 29, 2013: Atopix Therapeutics Receives Biomedical Catalyst Grant To Pursue Development Of OC459 In Treatment Of Atopic Dermatitis 48 Jul 15, 2011: Oxagen Announces Publication Of Phase IIa Asthma Trial Data For OC000459 Which Shows Promise As New Oral Treatment For Asthma And Related Disorders 49 May 23, 2011: Actelion's CRTH2 Antagonist Meets primary Endpoint In Phase II Study In Patients With Seasonal Allergic Rhinitis 49 Dec 09, 2009: Oxagen Announces Completion Of Recruitment In Phase IIb Dose Range-Finding Clinical Trial In New Oral Treatment For Asthma 50 Dec 09, 2009: Oxagen Completes Recruitment Of Patients For Phase IIb Clinical Trial Of OC000459 For Asthma 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13 Number of Products by Stage and Mechanism of Actions, H2 2017 14 Number of Products by Stage and Route of Administration, H2 2017 15 Number of Products by Stage and Molecule Type, H2 2017 16 Pipeline by Allergan Plc, H2 2017 17 Pipeline by Boehringer Ingelheim GmbH, H2 2017 17 Pipeline by Brickell Biotech Inc, H2 2017 18 Pipeline by Idorsia Ltd, H2 2017 18 Pipeline by Merck & Co Inc, H2 2017 19 Pipeline by Novartis AG, H2 2017 19 Pipeline by Oxagen Ltd, H2 2017 20 Pipeline by Pulmagen Therapeutics LLP, H2 2017 20 Dormant Products, H2 2017 38 Dormant Products, H2 2017 (Contd..1), H2 2017 39 Dormant Products, H2 2017 (Contd..2), H2 2017 40 Discontinued Products, H2 2017 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
